Hyperparathyroidism

Disease State and Clinical Science Training Resource, SMi Source™, Upgrades Learning Experience with Closed Captioning and an Expansion of Rare Disease Coverage

Retrieved on: 
Tuesday, October 31, 2023
Hyperparathyroidism, Rare disease, Biomarker, Biotechnology, MD, Narration, Sickle cell disease, Comprehension, Doctor of Philosophy, Research, Type 2 diabetes, Learning, Disease, Biology, Rising Medical Solutions, Language, Safety, Chief commercial officer, Blog, SAN, Pharmaceutical industry, Tutoring

Responding to the needs and feedback of its customers, ScienceMedia recognizes the importance of inclusivity and accessibility in training.

Key Points: 
  • Responding to the needs and feedback of its customers, ScienceMedia recognizes the importance of inclusivity and accessibility in training.
  • By incorporating closed captioning into their training resources, ScienceMedia strengthens the learning opportunities for all individuals, regardless of their hearing abilities.
  • Studies have shown that closed captioning significantly enhances the learning experience.
  • For ongoing insight about proven disease state and therapeutic training content, follow ScienceMedia via LinkedIn or our blog .

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly

Retrieved on: 
Sunday, September 10, 2023
Injection, Endocrinology, Obesity, Carcinoid syndrome, Diabetes, Diarrhea, FISU World University Games, Hyperparathyroidism, Hyperinsulinism, Congenital adrenal hyperplasia, PAL, Medicine, Arthralgia, Abdominal pain, ID, Acromegaly, Patient, Webcast, Nausea, Medical school, G protein, PBO, Headache, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Disease, Pharmaceutical industry

The frequency of participants with at least one treatment emergent adverse event (TEAE) was comparable in the paltusotine (PAL) treatment arm vs placebo (PBO) arm (80% vs. 100% respectively).

Key Points: 
  • The frequency of participants with at least one treatment emergent adverse event (TEAE) was comparable in the paltusotine (PAL) treatment arm vs placebo (PBO) arm (80% vs. 100% respectively).
  • The frequency of adverse events considered related to acromegaly was notably lower in paltusotine treated participants compared to placebo treated participants (30% vs. 86% respectively).
  • “We designed paltusotine to be the preferred therapeutic option for people living with acromegaly.
  • The Company is also conducting an open-label Phase 2 study to evaluate paltusotine in patients with carcinoid syndrome and intends to report preliminary results later this year.

Crinetics to Highlight Broad Pipeline at ENDO 2023

Retrieved on: 
Friday, June 9, 2023
ENDO, Entrepreneurship, Maintenance, Endocrinology, Endocrine system, TSHR, Peptide hormone, FISU World University Games, Policy, Foot, Hyperparathyroidism, Saint Andrew's Society, Acromegaly, PTH1R, Physician, Pharmacokinetics, SAN, Endocrine Society, Primary hyperparathyroidism, Neuroendocrinology, Drug discovery, Medical school, Liver, SST2, Graves' ophthalmopathy, Hyperthyroidism, Memory, Pharmaceutical industry, Vaccine, Medical imaging, Safety

SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced upcoming presentations that will highlight the company’s pipeline at ENDO 2023, the Endocrine Society’s annual meeting, which is being held June 15-18, 2023 in Chicago, Illinois.

Key Points: 
  • SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced upcoming presentations that will highlight the company’s pipeline at ENDO 2023, the Endocrine Society’s annual meeting, which is being held June 15-18, 2023 in Chicago, Illinois.
  • An upcoming oral presentation will review previously reported two-year data from the company’s ACROBAT Advance open-label extension study of paltusotine in acromegaly.
  • I would like to thank the Endocrine Society for awarding this prize, which is a testament to all of the groundbreaking work being done by the Crinetics team.”
    The posters and oral presentations will be made available on the Crinetics website in accordance with the ENDO embargo policy.
  • For attendees of ENDO 2023, Crinetics staff will be available to address questions and discuss pipeline programs at the company booth (#1623).

Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

Retrieved on: 
Thursday, May 4, 2023
Yale University, Amgen, Medical Affairs Bureau, Partnership, Senior, Chronic kidney disease, Nephrology, Hyperparathyroidism, Immunoglobulin A, Vera, AstraZeneca, Associate, Kidney disease, Patient, Kidney, Chief Medical Officer (Ireland), Therapy, CKD, Hyperkalemia, Pharmaceutical industry, IgA nephropathy, Medicine

BRISBANE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced the appointment of Kerry Cooper, M.D., to the role of Senior Vice President, Medical Affairs, where he will report to Chief Medical Officer Celia Lin and be responsible for overseeing medical affairs strategy and scientific communications.

Key Points: 
  • BRISBANE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced the appointment of Kerry Cooper, M.D., to the role of Senior Vice President, Medical Affairs, where he will report to Chief Medical Officer Celia Lin and be responsible for overseeing medical affairs strategy and scientific communications.
  • He has led medical affairs strategies for drug development programs in chronic kidney disease (CKD), hyperparathyroidism, hyperkalemia and other renal conditions.
  • Over twelve years, he served in leadership roles in medical affairs at several leading pharmaceutical companies, including AstraZeneca and Amgen, where he served as Global Medical Affairs Leader for Nephrology.
  • He joins Vera from ProKidney, where he led the development of the medical affairs function.

End Drug Shortages Alliance Releases Report for Drugs Impacted by Pharmaceutical Plant Closure

Retrieved on: 
Wednesday, March 15, 2023
Other Manufacturing, Medical Supplies, Hospitals, Transport, Manufacturing, Practice Management, General Health, Pharmaceutical, Health, Logistics, Supply Chain Management, Oklahoma Hospital Association, Risk, Dimercaprol, Hyperparathyroidism, Supraventricular tachycardia, ASHP, Patient, EDSA, Calcitriol, Organic acid, Knowledge, Akorn, Physostigmine, East End Drugs, Bankruptcy, Adenosine, CHA, Anticholinergic, Mayo Clinic, Kidney, Pharmaceutical industry, Risk management, Medical device, Nursing, Vizient, Inc.

The End Drug Shortages Alliance (EDSA) today released a report assessing the impact to the U.S. market caused by the recent closure of a drug manufacturer.

Key Points: 
  • The End Drug Shortages Alliance (EDSA) today released a report assessing the impact to the U.S. market caused by the recent closure of a drug manufacturer.
  • “Transparency regarding drug shortages is important to ensure patient care remains uninterrupted,” said Mittal Sutaria, senior vice president, Vizient pharmacy contract and program services and EDSA board member.
  • Clinicians and providers, to exercise a stewardship mindset and review purchasing and formulary status to determine conservation and mitigation strategies.
  • “Advance knowledge of supply disruptions is part of the transparency that the End Drug Shortages Alliance has advocated for since forming.

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 28, 2023
Momentum, Hyperparathyroidism, Diabetes, Safety, SRL, Innovation, Volunteering, Octreotide, Congenital hyperinsulinism, Research, Clinical trial, FDA, Investment, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, Trial of the century, MAD, MHRA, ACTH, Glomus tumor, Congenital adrenal hyperplasia, Sequoyah, SAN, Polycystic kidney disease, Medicines and Healthcare products Regulatory Agency, MAA, Pharmacodynamics, Graves' ophthalmopathy, Adrenocorticotropic hormone, Food, DSM-IV codes, Carcinoid syndrome, Acromegaly, Health care, Risk management, Pharmaceutical industry, Cryptocurrency, Pharmacokinetics

Pending a successful outcome from the PATHFNDR studies, an NDA submission in acromegaly is expected in 2024

Key Points: 
  • Pending a successful outcome from the PATHFNDR studies, an NDA submission in acromegaly is expected in 2024
    SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the fourth quarter and year ended December 31, 2022.
  • PATHFNDR-2 is the second placebo-controlled Phase 3 clinical study of oral paltusotine in participants with acromegaly.
  • Enrollment is ongoing in the study and the company is aggressively navigating prolonged pandemic-related and geopolitical disruptions in certain key study regions.
  • In April 2022, Crinetics successfully completed an underwritten follow-on offering of its common stock, raising gross proceeds of approximately $125 million.

BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1

Retrieved on: 
Thursday, December 22, 2022
ENDO, Urine, Standard of care, PTH, Cancer, Autosome, Blood, Endocrine Society, Geisinger Health System, UK Biobank, Calcium, Hypercalcaemia, PALO, Disease, Patient, Hyperparathyroidism, Safety, Maintenance, High society, Conference, Hypocalcemia, Quality of life, Calcium-sensing receptor, Genetics, Pharmaceutical industry, Agriculture, Dietary supplement, SOC, EU

While SoC may address acute symptoms related to hypocalcemia, it may exacerbate high urine calcium levels, which can cause renal complications1.

Key Points: 
  • While SoC may address acute symptoms related to hypocalcemia, it may exacerbate high urine calcium levels, which can cause renal complications1.
  • “The pivotal CALIBRATE study will evaluate the potential for encaleret to provide a meaningful benefit to patients and families living with ADH1.
  • In the Phase 2b study encaleret was generally well-tolerated, with no observed safety signals of potential clinical concern, and restored normal mineral homeostasis.
  • The Phase 3 multicenter, international, randomized, open-label, two-arm, three-period clinical study will assess the efficacy and safety of encaleret for 24 weeks.

ProKidney Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

Retrieved on: 
Wednesday, July 20, 2022
Yale School of Medicine, Diagnosis, University, International Society, International Society of Nephrology, Kidney, Mortality, CKD, GLOBE, Industry, U.S. Securities and Exchange Commission, Â, Dialysis, Research, EMA, Partnership, Kidney failure, CMO, Private Securities Litigation Reform Act, Chronic kidney disease, Risk, Marketing, Amgen, Disease, American Society of Nephrology, COVID-19, Medical Affairs Bureau, Technology, FDA, Company, Security (finance), Patient, National Kidney Foundation, AstraZeneca, Therapy, Humanitarian use licenses, Internal medicine, Growth, Renal replacement therapy, Society, Hyperparathyroidism, Yale New Haven Hospital, Pharmaceutical industry, Nephrology, Nasdaq

as Senior Vice President of Medical Affairs.

Key Points: 
  • as Senior Vice President of Medical Affairs.
  • Dr. Cooper, who will report to Chief Medical Officer Dr. Libbie McKenzie, joins ProKidney from AstraZeneca, where he was Vice President, U.S. Medical Affairs Renal Division.
  • He led medical teams on nephrology programs, including Lokelma, and contributed to cross functional teams advancing therapeutics utilized by CKD patients.
  • Dr. Libbie McKenzie, CMO of ProKidney, said: On behalf of our entire team, I am delighted to welcome Dr. Cooper to ProKidney.

1 in 50 Women Will Suffer From Parathyroid Disease

Retrieved on: 
Wednesday, July 6, 2022
People, Well, Kidney failure, Diagnosis, Surgeon, View, Patient, Arrhythmia, Heart, Hyperparathyroidism, Research, University, Tissue, Brain, Parathyroid gland, Anatomy, Chronic fatigue, Element, Blood, Disease, Mark (given name), Neck, Depression, Gastrointestinal tract, Calcium, Endocrine system, Human body, Kidney, Woman, Risk, Cancer, Parathyroid disease, Neoplasm, Exocrine gland, Parathyroid hormone, Busch Gardens, Human, Mammal, Hospital, Headache, Hypertension, Osteoporosis, Amnesia, PTH, Bone pain, Muscle, Eating, Multimedia, Medical imaging, Phosphorus, Pharmaceutical industry, Dentistry, EU

Hyperparathyroidism (parathyroid disease) is the most common condition of parathyroid glands, caused by the development of a tumor on one or more parathyroid glands.

Key Points: 
  • Hyperparathyroidism (parathyroid disease) is the most common condition of parathyroid glands, caused by the development of a tumor on one or more parathyroid glands.
  • In fact, the Norman Parathyroid Center cites that 1 in 50 women will suffer from parathyroid disease at some point in their lives.
  • The surgeons at the Norman Parathyroid Center are by far the most experienced parathyroid surgeons in the world performing 70+ parathyroid operations per week.
  • Located in Tampa, Florida, the Norman Parathyroid Center is the leading parathyroid gland tumor treatment center in the world, performing nearly 3,800 parathyroid operations annually.

World's most experienced adrenal surgeon now operating exclusively at the Hospital for Endocrine Surgery

Retrieved on: 
Wednesday, January 26, 2022
Well, Center, Patient, Nuclear medicine, Thyroid, RFA, Pathology, Adrenal tumor, Tampa International Airport, Hyperparathyroidism, Yale University, Exocrine gland, Surgeon, Multimedia, Neoplasm, Infarction, Stroke, American Association of Clinical Endocrinologists, Endocrine surgery, Hospital, Radiology, Radiofrequency ablation, Doctor of Philosophy, Physician, MD, Pharmaceutical industry, Dentistry

With this move, the Carling Adrenal Center joins its sister surgeons at the Norman Parathyroid Center , Clayman Thyroid Center and Scarless Thyroid Surgery Center at the Hospital for Endocrine Surgery for the first time under one roof in the same hospital.

Key Points: 
  • With this move, the Carling Adrenal Center joins its sister surgeons at the Norman Parathyroid Center , Clayman Thyroid Center and Scarless Thyroid Surgery Center at the Hospital for Endocrine Surgery for the first time under one roof in the same hospital.
  • "We are very enthusiastic to move the Carling Adrenal Center into the newly opened Hospital for Endocrine Surgery," said Dr. Tobias Carling.
  • "Our national and international adrenal tumor patients deserve to be treated at the world's premier Hospital for Endocrine Surgery.
  • The Norman Parathyroid Center, Clayman Thyroid Center, Carling Adrenal Center, and the Scarless Thyroid Center are now operating exclusively at the Hospital for Endocrine Surgery.